Sector
Healthcare
Industry
Medical - Diagnostics & Research
Employees
19
First IPO Date
November 05, 2021
| Name | Title | Pay | Year Born |
| Guido Baechler | Chief Executive Officer & Executive Director | 0 | 1965 |
| Christopher Von Toerne | Chief Operating Officer | 0 | 1972 |
| Stefan Erlach | Head of Human Resources | 0 | N/A |
| William J. Caragol | Chief Financial Officer & Senior Vice President | 0 | 1967 |
Mainz Biomed B.V. is a German company specializing in molecular genetics for the development of cancer diagnostics. The firm engineers both in-vitro diagnostic (IVD) tools and assays designed exclusively for research, primarily catering to clinical applications within human genetics. Among its key offerings is ColoAlert, a screening test for detecting colorectal cancer. Additionally, they are developing PancAlert, a promising product candidate intended for pancreatic cancer screening. Beyond cancer, Mainz Biomed also provides GenoStrip, a molecular genetic solution for identifying pathogens in various environments. Established in 2008, the company maintains its headquarters in Mainz, Germany.